Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)

被引：0

作者：

Hodi, F. S. ^{[1
]}

Chiarion-Sileni, V. ^{[2
]}

Gonzalez, R. ^{[3
]}

Grob, J. J. ^{[4
,5
]}

Rutkowski, P. ^{[6
]}

Cowey, C. L. ^{[7
]}

Lao, C. ^{[8
]}

Schadendorf, D. ^{[9
,10
]}

Wagstaff, J. ^{[11
]}

Dummer, R. ^{[12
]}

Ferrucci, P. F. ^{[13
]}

Smylie, M. ^{[14
]}

Hill, A. G. ^{[15
]}

Hogg, D. ^{[16
]}

Marquez-Rodas, I. ^{[17
]}

Jiang, J. ^{[18
]}

Rizzo, J. ^{[19
]}

Larkin, J. ^{[20
]}

Wolchok, J. ^{[21
,22
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[2] IRCCS, IOV, Melanoma & Esophageal Canc Unit, Padua, Italy

[3] Univ Colorado, Ctr Canc, Div Med Oncol, Denver, CO 80262 USA

[4] Aix Marseille Univ, Serv Dermatol, Marseille, France

[5] Hosp CHU Timone, AP HM, Marseille, France

[6] Maria Sklodowska Curie Inst, Ctr Oncol, Dept Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland

[7] Baylor Charles A Sammons Canc Ctr, Texas Oncol, Melanoma & Genitourinary Oncol Program, Dallas, TX USA

[8] Univ Michigan, Oncol, Ann Arbor, MI 48109 USA

[9] Univ Essen Gesamthsch, Hautklin, Dept Dermatol, Essen, Germany

[10] German Canc Consortium, Essen, Germany

[11] Swansea Univ, Coll Med, Med Oncol, Swansea, W Glam, Wales

[12] Univ Spital, Dermatol, Zurich, Switzerland

[13] European Inst Oncol, Oncol, Milan, Italy

[14] Cross Canc Inst, Dept Oncol, Edmonton, AB, Canada

[15] Tasman Oncol Res, Med Oncol, Southport, Qld, Australia

[16] Princess Margaret Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada

[17] Gen Univ Hosp Gregorio Maranon, Med Oncol, Madrid, Spain

[18] Bristol Myers Squibb, Global Biometr Sci, Princeton, NJ USA

[19] Bristol Myers Squibb, Oncol Clin Dev, Princeton, NJ USA

[20] Royal Marsden Hosp NHS Fdn Trust, Med, London, England

[21] Mem Sloan Kettering Canc Ctr, Melanoma & Immunotherapeut, 1275 York Ave, New York, NY 10021 USA

[22] Weill Cornell Med Coll, New York, NY USA

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA44

引用

页码：735 / 735

页数：1

共 50 条

[1] Overall Survivalwith Nivolumab (NIVO) and Ipilimumab (IPI) Combination Therapy in a Phase III Trial of Advanced Melanoma (CHECKMATE 067)
Larkin, J.
Chiarion-Sileni, V.
Gonzalez, R.
Rutkowski, P.
Grob, J-J
Cowey, C. L.
Lao, C. D.
Schadendorf, D.
Ferrucci, P. F.
Smylie, M.
Dummer, R.
Hill, A.
Haanen, J.
Maio, M.
McArthur, G.
Walker, D.
Rollin, L.
Horak, C.
Hodi, F. S.
Wolchok, J. D.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 48 - 48
[2] First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma
Turajlic, S.
Gore, M.
Larkin, J.
ANNALS OF ONCOLOGY, 2018, 29 (03) : 542 - 543
[3] 5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO plus IPI) combination therapy in advanced melanoma
Larkin, J. M. G.
Chiarion-Sileni, V.
Gonzalez, R.
Grob, J. J.
Rutkowski, P.
Lao, C.
Cowey, C. L.
Schadendorf, D.
Wagstaff, J.
Dummer, R.
Ferrucci, P. F.
Smylie, M.
Hogg, D.
Hill, A.
Marquez-Rodas, I.
Haanen, J. B. A. G.
Rizzo, J.
Balogh, A.
Hodi, F. S.
Wolchok, J.
ANNALS OF ONCOLOGY, 2019, 30 : 904 - 905
[4] 10-y survival outcomes from the phase III CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma
Larkin, J.
Sileni, V. Chiarion
Marqueste, C. Gaudy
Rutkowski, P.
Medina, T. M.
Lao, C. D.
Cowey, C. L.
Schadendorf, D.
Wagstaff, J.
Dummer, R.
Queirolo, P.
Walker, J.
Butler, M. O.
Hill, A. G.
Marquez-Rodas, I.
Haanen, J. B. A. G.
Nassar, A.
Askelson, M.
Hodi, F. S.
Wolchok, J. D.
ANNALS OF ONCOLOGY, 2024, 35 : 1234 - 1235
[5] Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Hodi, Frank Stephen
Chiarion-Sileni, Vanna
Gonzalez, Rene
Grob, Jean-Jacques
Rutkowski, Piotr
Cowey, Charles Lance
Lao, Christopher D.
Schadendorf, Dirk
Wagstaff, John
Dummer, Reinhard
Ferrucci, Pier Francesco
Smylie, Michael
Hill, Andrew
Hogg, David
Marquez-Rodas, Ivan
Jiang, Joel
Rizzo, Jasmine
Larkin, James
Wolchok, Jedd D.
LANCET ONCOLOGY, 2018, 19 (11): : 1480 - 1492
[6] Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients with advanced melanoma (CheckMate 067)
Larkin, James
Chiarion-Sileni, Vanna
Gonzalez, Rene
Rutkowski, Piotr
Grob, Jean-Jacques
Cowey, C. Lance
Lao, Christopher D.
Schadendorf, Dirk
Ferrucci, Pier Francesco
Smylie, Michael
Dummer, Reinhard
Hill, Andrew
Haanen, John
Maio, Michele
McArthur, Grant
Walker, Dana
Rollin, Linda
Horak, Christine
Hodi, F. Stephen
Wolchok, Jedd D.
CANCER RESEARCH, 2017, 77
[7] Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.
Hodi, F. Stephen
Chiarion-Sileni, Vanna
Lewis, Karl D.
Grob, Jean-Jacques
Rutkowski, Piotr
Lao, Christopher D.
Cowey, Charles Lance
Schadendorf, Dirk
Wagstaff, John
Dummer, Reinhard
Queirolo, Paola
Smylie, Michael
Butler, Marcus O.
Hill, Andrew Graham
Marquez-Rodas, Ivan
Haanen, John B. A. G.
Durani, Piyush
Wang, Peter
Wolchok, Jedd D.
Larkin, James
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[8] Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
Ascierto, Paolo Antonio
Del Vecchio, Michele
Mackiewicz, Andrzej
Robert, Caroline
Chiarion-Sileni, Vanna
Arance, Ana
Lebbe, Celeste
Svane, Inge Marie
McNeil, Catriona
Rutkowski, Piotr
Loquai, Carmen
Mortier, Laurent
Hamid, Omid
Bastholt, Lars
Dreno, Brigitte
Schadendorf, Dirk
Garbe, Claus
Nyakas, Marta
Grob, Jean-Jacques
Thomas, Luc
Liszkay, Gabriella
Smylie, Michael
Hoeller, Christoph
Ferraresi, Virginia
Grange, Florent
Gutzmer, Ralf
Pikiel, Joanna
Hosein, Fareeda
Simsek, Burcin
Maio, Michele
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
[9] Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (vol 19, pg 1480, 2018)
Hodi, F. S.
Chiarion-Sileni, V
Gonzalez, R.
LANCET ONCOLOGY, 2018, 19 (12): : E668 - E668
[10] Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (vol 19, pg 1480, 2018)
Hodi, F. S.
Chiarion-Sileni, V
Gonzalez, R.
LANCET ONCOLOGY, 2018, 19 (11): : E581 - E581

← 1 2 3 4 5 →